Posts Tagged ‘invention’

Share via email

By: Mark R. Malek

I was reading through my daily update this morning from Patently-O and noticed a bulletin that the Board of Patent Appeals and Interferences has changed it’s name to the Patent Trial and Appeal Board (PTAB).  Dennis Crouch indicated that this information was obtained from this alert.

This is just one of the many change that is coming from the America Invents Act (AIA).  The change is not due to a desire to have a different name.  Not by a long shot.  This is a product of the First to File system that is coming into place.  Interferences were a tool that currently can be used by inventors when two different entities invented the same thing at around the same time.  In short, when two applications were pending that were directed to the same invention, one party can request that an “interference” be declared.  After an interference is declared, the Board of Patent Appeals and Interferences (BPAI) would determine who was the “first to invent.”

Well, the AIA does away with “first to invent” and moves the United States to a “first to file” system.  In that case, we don’t need interferences any more.  The protection goes to the inventor that filed their application first.  Yes, yes, I am very much so simplifying this, but I just wanted to let you know that this is more than just a desire to change names.  The PTAB will still be carrying out many of the other functions that the BPAI carried out, i.e., appeals of Examiner’s decisions, appeals of reexaminations, inter partes review, post grant review, etc.

Many of these changes are set to take effect on September 16, 2012.  Here at the firm, the patent department is gearing up for the changes. I will be posting more on what inventors need to be on the lookout for as many of the provisions of AIA are implemented.

Share via email

By: Mark R. Malek

Ever since I started practicing patent law, one of the things that has continuously driven me nuts is when I hear people calling a patent a “monopoly” on a particular area of technology.  I’ll get into more detail below, but in essence, that is just not true.  This is one of the biggest mischaracterizations of patent law for a number of reasons.

First and foremost, the patent right does not provide someone with the right to make something, use something or sell something.  Close, but not exactly right.  All you have to do is ask yourself the following:  do I need a patent to produce something?  The answer here is a resounding NO.  The patent right provides the patent owner with the right to exclude others from making, using, selling, or offering to sell a product, process, etc. that is covered by the claims of the patent.  This is a very small distinction, but I always go back to the example that my professor in law school provided (many of you know this professor – Gene Quinn, founder of IPWatchdog.com and the partner in charge of our DC Office.  Incidentally, Gene Quinn posted a great article about this a couple of years ago). The example was “you can get a patent on a nuclear bomb – do you think that the government will ever let you make it?  Of course not.”

So here is that the patent right only gives you the right to exclude others from using your invention, it does not give you the right to make the invention.  I do understand some of the other arguments that support the fact that patents can be “monopoly like.”  In its purest form, a patent can act as a barrier to entry into the market.  In other words, the patent holder can bar others from entering the market, but to be fair, that barrier only encompasses the very specific space to which the claims of the patent are directed.  Due to the inventive nature of society, a great deal of people and companies are continuously improving technology.  That means that known technology is getting better every day.

Let’s take the cell phone, for example.  How far have we come in 15 or 20 years?  Do you remember the bag phones, or the phones that were like gigantic bricks (bringing back memories of Miami Vice, right?).  Now, due to the rapid advances in technology, I am able to achieve so much with my iPhone.  I could, if I have a ton of patience, even post this article from my iPhone.  Those of you who know me, however, know that such patience waived bye-bye to me years ago!

The point here is that it is not as though one company advanced the cell phone.  It is not as though there is only one cell phone manufacturer.  Why is that?  It is because the patent system does not really allow for a patent as broad as a cell phone to issue.  Claims are limited to very specific portions or programs or components of a cell phone.  Therefore, there is no “monopoly” on a cell phone, but there certainly is a monopoly like feeling to an Apple iPhone because Apple has several patents that protect the various features of the iPhone.  The answer to this is any phone that operates on the Android platform.

I guess what I am trying to say is that I do not believe that the term “monopoly” is accurate to use when discussing inventions that are protected by patent rights.  I really would welcome an open discussion on this.  I know that there are intellectual property haters out there that thing that patents and copyrights only serve to restrict the markets, and I will post more on that in future articles.  In the mean time, please feel free to share your opinion on this topic.

Share via email

By: Mark R. Malek

The Florida Regional Independent Inventors Conference will be held on April 27 and 28 in Tampa, Florida.  “Senior USPTO officials, successful inventors and intellectual property experts will be on hand to provide a wealth of practical advice and information for novice and seasoned inventors.”  For more information on the conference please see this link at the USPTO.

“A pre-conference workshop on April 26 from 5-7 p.m. is included in the registration fee. It will cover the basics of the patent process. If you cannot attend, this session will be repeated as a breakout session on April 27.”  This is a great opportunity for inventors to get a lot of great information about the patent process.  Zies Widerman & Malek encourages our readers to attend the conference.

 

 

Share via email

By: Mark R. Malek

My last article discussed the possibility of obtaining a patent, but that the patent may still infringe on the claims of an existing patent.  Yes, this is a rare situation, but one that is possible nonetheless.

The scenario that was laid out in the last article indicated that you have invented a chair with five legs.  The clear advantage is that this chair is much more stable than the typical chair that you normally sit on with four legs.  You have now filed a patent application on your chair with five legs.  During the examination, the Examiner has cited a chair with four legs as prior art.  Although the Examiner allows your patent, the Examiner indicates in the “reasons for allowance” that none of the cited prior art discloses the advantageous fifth leg and, therefore, the claims in your patent application define over the cited prior art.

Fantastic – you now have a patent.  You now also start manufacturing and selling your chair with five legs.  All of a sudden, you one day receive a letter from the owner of the patent on the chair with four legs.  The patent owner is accusing you of infringing on the claims of the patent, and instructs you to cease & desist from further infringement.  The letter explains that your chair, although it has five legs, still infringes on the claims of the patent.  It goes on to specifically indicate that your chair has four legs, and other stuff, i.e., a fifth leg.

Now you must engage in an investigation to make sure that the claims of the letter are founded.  You probably go to your favorite website on intellectual property, Tactical IP, or even your other favorite website on intellectual property, LegalTeamUSA, you will read one of my articles about what it takes to infringe a patent.  In the above article, it was noted that in order to infringe a patent, you must meet the claim limitations of at least one of the claims.  In other words, your invention has to include all of the elements of at least one of the claims in the patent.  You quickly figure out that your chair with five legs does meet the claim limitations.  Now what?

Now you engage in some sort of settlement negotiation that will hopefully end in a mutually beneficial license for you to continue manufacturing and selling your very lucrative chair with five legs.  You also do some investigation into the success of the patent on the chair with four legs.  Perhaps there is a cross licensing opportunity here.  I will discuss cross licensing in another post.  In short, cross licensing is where you grant a license to the owner of the patent on the chair with four legs a license to your patent so that the four leg chair patent owner can make chairs with five legs, and the four leg chair patent owner grants you a license so that you can continue to manufacture and sell your five leg chair patent.  Much of this is also laid out in my article about the various ways to make money from your invention.

Now you are asking how this could have been avoided.  The answer is a clearance search – also known as a freedom to operate search.  These searches are quite thorough and quite expensive.  This is a really good article on patent searches on IPWatchdog.  I will go into more detail about clearance searches in another post.  Until then, happy inventing!

Share via email

Danie Roy

The Supreme Court finally ruled that the Prometheus Labs patents in Mayo v Prometheus are invalid.  I personally tip my hat to the court on this decision.  I’ve written about this case before, and I’ve done some general Pharamaceutically Speaking analysis on how 101 applies to pharma and personalized medicine. Because Prometheus was originally a 101 issue, we’ll start there.

As I said before in my Invention vs Observation article, some inventive step MUST be included. Simply observing a law of nature isn’t patentable. In this case, testing apparatus and SPECIFIC tests might be patentable. If, for example, you invent a blood draw vial that gives a test result on receiving at least X amount of blood, THAT is patentable. If you invent a diagnostic machine learning algorithm that can determine the presence of a disease (a very specific test, which a human could otherwise not reasonably perform), then of course that would be patentable. But, in such a case, that necessarily means that “if the blood level of the drug (or protein produced in response to it) is outside of the range Y to Z, then we need to adjust” is NOT patentable… that is an observation.

Hope you're not afraid of needles...

The court then went on to see if other parts of the methods were patentable. My 103 analysis kicks in here: testing blood levels for the efficacy of immunosuppressant therapy drugs has been around for a VERY LONG TIME (known since 1988 at the very latest).  The parts that weren’t simple observation really were well known in the art. I’m no pharmacist or doctor, but if you ask anyone with an autoimmune disorder how often they have to go get their blood levels checked for whatever immunosuppressant they are on, you’re going to get an answer in the range of every week to every few months.

Perhaps, if the process were more involved than checking the level of the drug itself, such as checking levels of proteins or metabolites that could be produced by the presence of the drug, as well as taking into account other factors that might influence those levels, you might have a patentable, inventive process. Simply administering a drug and seeing how much is maintained in the body, however, isn’t particularly inventive.

Don’t believe me?  Let’s go through Claim 1.

A method of optimizing therapeutic efficacy for treatment of an immune-mediated gastrointestinal disorder, comprising:

Okay, we’ve established this is for treatment of an immune disorder.

(a) administering a drug providing 6-thioguanine to a subject having said immune-mediated gastrointesti­nal disorder; and

Administer a drug.

(b) determining the level of 6-thioguanine in said subject having said immune-mediated gastrointesti­nal disorder,

Check to see how much of the drug is in the person’s system.

wherein the level of 6-thioguanine less than about 230 pmol per 8×108 red blood cells indicates a need to increase the amount of said drug subsequently admin­istered to said subject and

We’re clarifying that we are checking the blood for a specific minimum level of the drug.

wherein the level of 6-thioguanine greater than about 400 pmol per 8×108 red blood cells indicates a need to decrease the amount of said drug subsequently administered to said subject.

…and checking the blood for a specific maximum level of the drug.

That’s Claim 1. It’s…shockingly basic. And, while it can be considered personalized medicine, the field of personalized medicine shouldn’t be too horribly affected. After all, drugs and tools are still patentable… simple correlations, or correlation observations, on the other hand, are (and rightly should be) out of the question.


Subscribe

Login



SATURDAY, MAY 18, 2013

Bad Behavior has blocked 8497 access attempts in the last 7 days.